Amarin Corporation plc (AMRN)
USD 0.4
(0.32%)
USD 0.4
(0.32%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -67.58 Million USD | 81.1% |
| 2022 | -92.34 Million USD | -514.47% |
| 2021 | 22.28 Million USD | 213.36% |
| 2020 | -19.65 Million USD | 19.05% |
| 2019 | -24.27 Million USD | 77.57% |
| 2018 | -108.22 Million USD | -137.57% |
| 2017 | -45.55 Million USD | 30.58% |
| 2016 | -65.62 Million USD | 33.19% |
| 2015 | -98.22 Million USD | -2.36% |
| 2014 | -95.95 Million USD | 47.31% |
| 2013 | -182.1 Million USD | -55.98% |
| 2012 | -116.75 Million USD | -164.37% |
| 2011 | -44.16 Million USD | 2.08% |
| 2010 | -45.1 Million USD | 13.77% |
| 2009 | -52.3 Million USD | -85.6% |
| 2008 | -28.18 Million USD | 30.82% |
| 2007 | -40.73 Million USD | -30.72% |
| 2006 | -31.16 Million USD | -64.8% |
| 2005 | -18.9 Million USD | -70.47% |
| 2004 | -11.09 Million USD | 71.43% |
| 2003 | -38.82 Million USD | -18.86% |
| 2002 | -32.66 Million USD | -543.21% |
| 2001 | -5.07 Million USD | -98.28% |
| 2000 | -2.56 Million USD | 62.39% |
| 1999 | -6.81 Million USD | 59.46% |
| 1998 | -16.8 Million USD | -107.41% |
| 1997 | -8.1 Million USD | 55.74% |
| 1996 | -18.3 Million USD | -497.83% |
| 1995 | 4.6 Million USD | -75.4% |
| 1994 | 18.7 Million USD | 1600.0% |
| 1993 | 1.1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -25.16 Million USD | -4697.65% |
| 2024 Q2 | -524.59 Thousand USD | 96.14% |
| 2024 Q1 | -13.57 Million USD | -192.06% |
| 2023 Q4 | -4.64 Million USD | 78.33% |
| 2023 Q2 | -23.95 Million USD | -38.16% |
| 2023 FY | -17.45 Million USD | 81.1% |
| 2023 Q3 | -21.45 Million USD | 10.47% |
| 2023 Q1 | -17.34 Million USD | -77.57% |
| 2022 Q1 | -28.3 Million USD | -275.46% |
| 2022 Q2 | -62.83 Million USD | -121.97% |
| 2022 Q4 | -9.76 Million USD | -630.18% |
| 2022 FY | -92.34 Million USD | -514.47% |
| 2022 Q3 | 1.84 Million USD | 102.93% |
| 2021 FY | 22.28 Million USD | 213.36% |
| 2021 Q3 | -13.07 Million USD | -249.01% |
| 2021 Q1 | -1.33 Million USD | -118.59% |
| 2021 Q2 | 8.77 Million USD | 759.13% |
| 2021 Q4 | 16.13 Million USD | 223.41% |
| 2020 Q4 | 7.15 Million USD | 203.14% |
| 2020 FY | -19.65 Million USD | 19.05% |
| 2020 Q3 | -6.94 Million USD | -266.99% |
| 2020 Q2 | 4.15 Million USD | 117.3% |
| 2020 Q1 | -24.02 Million USD | -537.69% |
| 2019 FY | -24.27 Million USD | 77.57% |
| 2019 Q4 | 5.49 Million USD | 221.51% |
| 2019 Q3 | -4.51 Million USD | -79.71% |
| 2019 Q2 | -2.51 Million USD | 88.94% |
| 2019 Q1 | -22.73 Million USD | 28.43% |
| 2018 Q4 | -31.77 Million USD | -42.79% |
| 2018 FY | -108.22 Million USD | -137.57% |
| 2018 Q1 | -21.89 Million USD | -206.18% |
| 2018 Q2 | -32.3 Million USD | -47.53% |
| 2018 Q3 | -22.25 Million USD | 31.13% |
| 2017 Q3 | -8.44 Million USD | 25.88% |
| 2017 Q2 | -11.39 Million USD | 38.57% |
| 2017 FY | -45.55 Million USD | 30.58% |
| 2017 Q1 | -18.55 Million USD | -44.27% |
| 2017 Q4 | -7.15 Million USD | 15.35% |
| 2016 Q4 | -12.86 Million USD | 15.76% |
| 2016 Q3 | -15.26 Million USD | -6.07% |
| 2016 Q2 | -14.39 Million USD | 37.7% |
| 2016 Q1 | -23.1 Million USD | -24.06% |
| 2016 FY | -65.62 Million USD | 33.19% |
| 2015 Q2 | -26.73 Million USD | 1.15% |
| 2015 Q4 | -18.62 Million USD | 27.86% |
| 2015 Q3 | -25.81 Million USD | 3.45% |
| 2015 Q1 | -27.04 Million USD | -33.91% |
| 2015 FY | -98.22 Million USD | -2.36% |
| 2014 FY | -95.95 Million USD | 47.31% |
| 2014 Q1 | -25.57 Million USD | 22.25% |
| 2014 Q3 | -24.94 Million USD | 1.17% |
| 2014 Q2 | -25.24 Million USD | 1.29% |
| 2014 Q4 | -20.2 Million USD | 19.02% |
| 2013 Q1 | -60.05 Million USD | -67.01% |
| 2013 FY | -182.1 Million USD | -55.98% |
| 2013 Q3 | -40.37 Million USD | 17.26% |
| 2013 Q4 | -32.88 Million USD | 18.54% |
| 2013 Q2 | -48.79 Million USD | 18.75% |
| 2012 Q1 | -18.78 Million USD | -52.4% |
| 2012 FY | -116.75 Million USD | -164.37% |
| 2012 Q4 | -35.95 Million USD | -4.8% |
| 2012 Q3 | -34.31 Million USD | -23.86% |
| 2012 Q2 | -27.7 Million USD | -47.48% |
| 2011 Q3 | -9.44 Million USD | 37.91% |
| 2011 Q4 | -12.32 Million USD | -30.48% |
| 2011 Q1 | -7.17 Million USD | 58.6% |
| 2011 FY | -44.16 Million USD | 2.08% |
| 2011 Q2 | -15.21 Million USD | -112.04% |
| 2010 Q2 | -10.58 Million USD | -43.0% |
| 2010 Q4 | -17.33 Million USD | -77.28% |
| 2010 Q1 | -7.4 Million USD | 0.0% |
| 2010 FY | -45.1 Million USD | 13.77% |
| 2010 Q3 | -9.77 Million USD | 7.68% |
| 2009 FY | -52.3 Million USD | -85.6% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q1 | -7.82 Million USD | -1.24% |
| 2008 FY | -28.18 Million USD | 30.82% |
| 2008 Q2 | 6.74 Million USD | 186.21% |
| 2007 Q3 | -6.89 Million USD | 58.08% |
| 2007 Q4 | -7.73 Million USD | -12.24% |
| 2007 FY | -40.73 Million USD | -30.72% |
| 2007 Q2 | -16.43 Million USD | -69.93% |
| 2007 Q1 | -9.67 Million USD | -18.22% |
| 2006 Q3 | -8.25 Million USD | -3.93% |
| 2006 Q1 | -6.77 Million USD | 63.38% |
| 2006 Q4 | -8.18 Million USD | 0.91% |
| 2006 FY | -31.16 Million USD | -64.8% |
| 2006 Q2 | -7.94 Million USD | -17.23% |
| 2005 Q1 | -3.39 Million USD | 47.65% |
| 2005 FY | -18.9 Million USD | -70.47% |
| 2005 Q3 | 250 Thousand USD | 104.41% |
| 2005 Q4 | -18.5 Million USD | -7502.4% |
| 2005 Q2 | -5.67 Million USD | -66.86% |
| 2004 Q3 | -1.26 Million USD | 52.4% |
| 2004 Q4 | -6.49 Million USD | -414.75% |
| 2004 Q1 | 1.04 Million USD | 102.59% |
| 2004 Q2 | -2.64 Million USD | -353.25% |
| 2004 FY | -11.09 Million USD | 71.43% |
| 2003 Q3 | -4.07 Million USD | 39.87% |
| 2003 Q1 | 14.87 Million USD | 117.44% |
| 2003 Q2 | -6.78 Million USD | -145.6% |
| 2003 FY | -38.82 Million USD | -18.86% |
| 2003 Q4 | -40.39 Million USD | -890.41% |
| 2002 Q4 | -85.3 Million USD | -675.5% |
| 2002 Q3 | 14.82 Million USD | 376.93% |
| 2002 Q2 | 3.1 Million USD | -82.35% |
| 2002 Q1 | 17.6 Million USD | 140.4% |
| 2002 FY | -32.66 Million USD | -543.21% |
| 2001 Q3 | 15.88 Million USD | -5.46% |
| 2001 Q4 | -43.57 Million USD | -374.39% |
| 2001 FY | -5.07 Million USD | -98.28% |
| 2001 Q1 | 5.81 Million USD | 137.24% |
| 2001 Q2 | 16.8 Million USD | 188.76% |
| 2000 Q1 | 4.32 Million USD | 0.0% |
| 2000 Q3 | 5.35 Million USD | 50.0% |
| 2000 Q2 | 3.56 Million USD | -17.48% |
| 2000 Q4 | -15.62 Million USD | -391.87% |
| 2000 FY | -2.56 Million USD | 62.39% |
| 1999 Q1 | 5.1 Million USD | 13.33% |
| 1999 Q3 | 3.3 Million USD | -44.07% |
| 1999 FY | -6.81 Million USD | 59.46% |
| 1999 Q2 | 5.9 Million USD | 15.69% |
| 1998 Q3 | -30.6 Million USD | -765.22% |
| 1998 FY | -16.8 Million USD | -107.41% |
| 1998 Q4 | 4.5 Million USD | 114.71% |
| 1998 Q2 | 4.6 Million USD | 0.0% |
| 1998 Q1 | 4.6 Million USD | -4.17% |
| 1997 Q2 | 6.1 Million USD | 17.31% |
| 1997 FY | -8.1 Million USD | 55.74% |
| 1997 Q1 | 5.2 Million USD | -1.89% |
| 1997 Q4 | 4.8 Million USD | 119.51% |
| 1997 Q3 | -24.6 Million USD | -503.28% |
| 1996 Q3 | -30.7 Million USD | -830.95% |
| 1996 FY | -18.3 Million USD | -497.83% |
| 1996 Q1 | 4.1 Million USD | 0.0% |
| 1996 Q4 | 5.3 Million USD | 117.26% |
| 1996 Q2 | 4.2 Million USD | 2.44% |
| 1995 Q2 | 7.3 Million USD | 0.0% |
| 1995 Q3 | -17.3 Million USD | -336.99% |
| 1995 Q1 | 7.3 Million USD | 0.0% |
| 1995 FY | 4.6 Million USD | -75.4% |
| 1995 Q4 | 4.1 Million USD | 123.7% |
| 1994 Q3 | 13.1 Million USD | 523.81% |
| 1994 Q4 | 7.3 Million USD | -44.27% |
| 1994 FY | 18.7 Million USD | 1600.0% |
| 1994 Q1 | 3.1 Million USD | 47.62% |
| 1994 Q2 | 2.1 Million USD | -32.26% |
| 1993 Q2 | 600 Thousand USD | 0.0% |
| 1993 FY | 1.1 Million USD | 0.0% |
| 1993 Q4 | 2.1 Million USD | 310.0% |
| 1993 Q3 | -1 Million USD | -266.67% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 71.507% |
| Alkermes plc | 414.12 Million USD | 116.321% |
| Agenus Inc. | -159.54 Million USD | 57.638% |
| Aptorum Group Limited | -10.52 Million USD | -542.268% |
| Ardelyx, Inc. | -63.27 Million USD | -6.815% |
| Dyadic International, Inc. | -8.22 Million USD | -721.265% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -5570.134% |
| Lantern Pharma Inc. | -17.87 Million USD | -278.06% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -236.43% |
| Novavax, Inc. | -566.51 Million USD | 88.069% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 7.387% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 17.772% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -248.06% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -539.856% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -27.221% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 82.237% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -178.064% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -78.478% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 47.601% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 19.456% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -285.358% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -53.574% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -172.05% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 51.386% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 76.047% |
| AlloVir, Inc. | -181.33 Million USD | 62.727% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 67.031% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -131.007% |
| Bicycle Therapeutics plc | -189.94 Million USD | 64.417% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 60.655% |
| ChromaDex Corporation | -5.59 Million USD | -1107.144% |
| Chimerix, Inc. | -93.06 Million USD | 27.375% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -49.938% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 41.764% |
| CRISPR Therapeutics AG | -222.53 Million USD | 69.629% |
| Precision BioSciences, Inc. | -43.73 Million USD | -54.536% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 64.523% |
| Fortress Biotech, Inc. | -142.34 Million USD | 52.517% |
| Fortress Biotech, Inc. | -142.34 Million USD | 52.517% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 30.817% |
| ImmuCell Corporation | -5.74 Million USD | -1075.837% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 49.722% |
| Immix Biopharma, Inc. | -16.14 Million USD | -318.732% |
| Incyte Corporation | 620.52 Million USD | 110.892% |
| Innoviva, Inc. | 176.7 Million USD | 138.248% |
| IO Biotech, Inc. | -91.44 Million USD | 26.087% |
| Jaguar Health, Inc. | -34.29 Million USD | -97.101% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 60.229% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 665.969% |
| ContextLogic Inc. | -328 Million USD | 79.394% |
| MiMedx Group, Inc. | 37.11 Million USD | 282.099% |
| MEI Pharma, Inc. | 14.54 Million USD | 564.778% |
| NextCure, Inc. | -67.63 Million USD | 0.072% |
| Onconetix, Inc. | -36.03 Million USD | -87.564% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -62.027% |
| Opthea Limited | -191.84 Million USD | 64.769% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -2356.115% |
| Vaxcyte, Inc. | -468.04 Million USD | 85.559% |
| PDS Biotechnology Corporation | -43.04 Million USD | -57.016% |
| Precigen, Inc. | -88.92 Million USD | 23.993% |
| Pharming Group N.V. | -4.87 Million USD | -1285.129% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 59.604% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -127.141% |
| PureTech Health plc | -146.19 Million USD | 53.77% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -229.842% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 71.312% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -178.064% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 75.333% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -130.636% |
| Acelyrin, Inc. | -422.06 Million USD | 83.986% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -524043.579% |
| Summit Therapeutics Inc. | -89.73 Million USD | 24.681% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -82.355% |
| Senti Biosciences, Inc. | -92.72 Million USD | 27.111% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 41.112% |
| Elevation Oncology, Inc. | -45.44 Million USD | -48.725% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -97.239% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -1614.54% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -2037.508% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -104.682% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -695.059% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 0.6% |
| Seer, Inc. | -103.46 Million USD | 34.674% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -2.781% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 6.04% |
| ESSA Pharma Inc. | -32.13 Million USD | -110.331% |
| GlycoMimetics, Inc. | -39.27 Million USD | -72.088% |
| GT Biopharma, Inc. | -13.57 Million USD | -397.849% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 69.169% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | -46.117% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 177.856% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -19.079% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -31.224% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -580.121% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 86.598% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -879.82% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -33.328% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 73.97% |
| Aptose Biosciences Inc. | -52.35 Million USD | -29.093% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -368.685% |
| Soligenix, Inc. | -7.69 Million USD | -778.001% |
| Century Therapeutics, Inc. | -146.54 Million USD | 53.879% |
| Kura Oncology, Inc. | -165.8 Million USD | 59.236% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 27.681% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -712.453% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -2623.523% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -942.381% |
| Autolus Therapeutics plc | -195.02 Million USD | 65.344% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 20.163% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 8.246% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -219.792% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 70.23% |
| GRI Bio, Inc. | -11.38 Million USD | -493.554% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -1396.729% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 48.482% |
| IGM Biosciences, Inc. | -263.46 Million USD | 74.346% |
| INmune Bio, Inc. | -29.74 Million USD | -127.255% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 38.898% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -77.511% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -322.971% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -328.563% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -10.622% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 37.14% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 75.512% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 66.738% |
| Verastem, Inc. | -92.08 Million USD | 26.602% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -43.392% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 63.296% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 42.906% |
| Histogen Inc. | -10.64 Million USD | -535.047% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -336.842% |
| Surrozen, Inc. | -45.78 Million USD | -47.637% |
| Organovo Holdings, Inc. | -15.08 Million USD | -348.018% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1227.797% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -14.012% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -31.766% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -167.358% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -785.489% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 60.54% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -39.506% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 13.576% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -344.051% |
| Apollomics, Inc. | -54.83 Million USD | -23.259% |
| Mesoblast Limited | -58.79 Million USD | -14.957% |
| Turnstone Biologics Corp. | -59.03 Million USD | -14.494% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 59.169% |
| Synaptogenix, Inc. | -8.31 Million USD | -712.956% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -363.376% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 26.287% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1310.591% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -665.329% |
| Exelixis, Inc. | 170.88 Million USD | 139.552% |
| Better Therapeutics, Inc. | -38.26 Million USD | -76.645% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 56.413% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 86.93% |
| NLS Pharmaceutics AG | -11.8 Million USD | -472.437% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -740.448% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -125.346% |
| Gritstone bio, Inc. | -154.63 Million USD | 56.292% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 1.849% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -294.719% |
| Avid Bioservices, Inc. | -18.67 Million USD | -261.859% |
| Insmed Incorporated | -709.62 Million USD | 90.476% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -330.777% |
| MediWound Ltd. | -15.29 Million USD | -342.041% |
| OmniAb, Inc. | -69.41 Million USD | 2.638% |
| Alector, Inc. | -151.74 Million USD | 55.458% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 37.409% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -29.608% |
| Zai Lab Limited | -366.57 Million USD | 81.562% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 78.664% |
| Aura Biosciences, Inc. | -84.99 Million USD | 20.476% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 72.469% |
| Immunic, Inc. | -99.22 Million USD | 31.883% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 52.788% |
| Veracyte, Inc. | -85.79 Million USD | 21.222% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 76.017% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -375.637% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -881.25% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -259.652% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 111.682% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -165.54% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 274.187% |
| TG Therapeutics, Inc. | 20.63 Million USD | 427.572% |
| Galecto, Inc. | -39.9 Million USD | -69.372% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -60.641% |
| Fortrea Holdings Inc. | 63.1 Million USD | 207.113% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 51.876% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -134.047% |
| XBiotech Inc. | -37.51 Million USD | -80.187% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 1.849% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -0.697% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 37.364% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -163.275% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -26.826% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 88.126% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 13.892% |
| Vaxxinity, Inc. | -58.28 Million USD | -15.961% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 34.829% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -203.724% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 21.788% |
| NexImmune, Inc. | -29.19 Million USD | -131.525% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -1102.605% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -363.523% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.67% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -165.478% |
| Scopus BioPharma Inc. | -11.71 Million USD | -476.942% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 46.807% |
| Ainos, Inc. | -13.2 Million USD | -411.782% |
| Pluri Inc. | -22.15 Million USD | -205.028% |
| Prothena Corporation plc | -191.03 Million USD | 64.62% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 51.037% |
| Celularity Inc. | -192.28 Million USD | 64.85% |
| Rallybio Corporation | -78.93 Million USD | 14.372% |
| Cue Biopharma, Inc. | -52.14 Million USD | -29.606% |
| MeiraGTx Holdings plc | -137.06 Million USD | 50.688% |
| Omeros Corporation | -164.53 Million USD | 58.921% |
| Humacyte, Inc. | -100.04 Million USD | 32.444% |
| Immunocore Holdings plc | -59.64 Million USD | -13.31% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -264.179% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -176.061% |
| Blueprint Medicines Corporation | -486.27 Million USD | 86.101% |
| CalciMedica, Inc. | -21.87 Million USD | -208.974% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 9.472% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 48.596% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 60.543% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 79.325% |
| Pulmatrix, Inc. | -14.74 Million USD | -358.535% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -89.084% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 23.944% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 86.884% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -0.055% |
| Cytokinetics, Incorporated | -496.2 Million USD | 86.379% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -96.368% |
| Nutriband Inc. | -4.87 Million USD | -1287.295% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -54.972% |
| Vor Biopharma Inc. | -126.03 Million USD | 46.374% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 101.593% |
| Evogene Ltd. | -26.39 Million USD | -156.102% |
| ProKidney Corp. | -151.52 Million USD | 55.394% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -4.731% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -778.652% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 88.872% |
| CorMedix Inc. | -48.95 Million USD | -38.054% |
| BioLineRx Ltd. | -49.69 Million USD | -36.008% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 40.802% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -77.527% |
| Atai Life Sciences N.V. | -125.47 Million USD | 46.133% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 17.211% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 16.977% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 72.855% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -119.87% |
| MediciNova, Inc. | -9.9 Million USD | -582.689% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 46.517% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -833.219% |
| GeoVax Labs, Inc. | -26.74 Million USD | -152.732% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 70.845% |
| Biomea Fusion, Inc. | -126.13 Million USD | 46.416% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 80.656% |
| Mereo BioPharma Group plc | -28.41 Million USD | -137.852% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 64.63% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 70.608% |
| Absci Corporation | -115.51 Million USD | 41.49% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -144.999% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 40.117% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 72.09% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -168.249% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 67.505% |
| Allakos Inc. | -196.05 Million USD | 65.526% |
| Imunon, Inc. | -21.03 Million USD | -221.382% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 38.925% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 163.0% |
| BioAtla, Inc. | -129.68 Million USD | 47.884% |
| NLS Pharmaceutics AG | -11.8 Million USD | -472.437% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -326.611% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 79.377% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -61.856% |
| XOMA Corporation | -41.84 Million USD | -61.508% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 35.775% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 44.37% |
| aTyr Pharma, Inc. | -54.91 Million USD | -23.069% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 22.692% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 60.902% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 73.438% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -214.861% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -722.964% |
| Akari Therapeutics, Plc | -16.8 Million USD | -302.166% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -764208.161% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 120.022% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -934.401% |
| UroGen Pharma Ltd. | -65.53 Million USD | -3.131% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 24.295% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -830.578% |
| Orgenesis Inc. | -53.63 Million USD | -26.012% |
| Entera Bio Ltd. | -8.89 Million USD | -660.184% |
| GH Research PLC | -41.22 Million USD | -63.961% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -162.906% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 18.621% |
| Xencor, Inc. | -138.63 Million USD | 51.249% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -1211.221% |
| Replimune Group, Inc. | -234.77 Million USD | 71.211% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -214.493% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -384.432% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -934.401% |
| Portage Biotech Inc. | -18.25 Million USD | -270.284% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -833.219% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 35.607% |
| OncoCyte Corporation | -25.13 Million USD | -168.889% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -497.867% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -489.924% |
| Purple Biotech Ltd. | 22.27 Million USD | 403.48% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -799.734% |
| scPharmaceuticals Inc. | -55.39 Million USD | -22.009% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -257.652% |
| HilleVax, Inc. | -133.34 Million USD | 49.313% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -460.943% |
| Tharimmune, Inc. | -9.45 Million USD | -614.822% |
| Genprex, Inc. | -31.07 Million USD | -117.496% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 64.086% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -115.406% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -8735.033% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -1140.848% |
| OKYO Pharma Limited | -15.74 Thousand USD | -429037.515% |
| Savara Inc. | -60 Million USD | -12.634% |
| Curis, Inc. | -48.33 Million USD | -39.841% |
| Daré Bioscience, Inc. | -30.83 Million USD | -119.158% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -1195.464% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -828.789% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -148.029% |
| BeiGene, Ltd. | -1.2 Billion USD | 94.404% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -238.969% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 86.127% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 27.831% |
| Erasca, Inc. | -141.52 Million USD | 52.243% |
| bluebird bio, Inc. | -244.26 Million USD | 72.33% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -1393.006% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 134.76% |
| DBV Technologies S.A. | -76.43 Million USD | 11.571% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -1393.006% |
| Moderna, Inc. | -4.23 Billion USD | 98.406% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -58.624% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -962.704% |
| Molecular Templates, Inc. | -10.46 Million USD | -545.786% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -0.522% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 82.06% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 52.838% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -29.994% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 56.266% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 67.526% |
| MacroGenics, Inc. | -168.24 Million USD | 59.827% |
| RenovoRx, Inc. | -11.39 Million USD | -493.085% |
| Adicet Bio, Inc. | -152.03 Million USD | 55.545% |
| Prime Medicine, Inc. | -191.29 Million USD | 64.668% |
| Aditxt, Inc. | -26.06 Million USD | -159.331% |
| Adagene Inc. | -23.71 Million USD | -184.943% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -824.584% |
| Quantum-Si incorporated | -111.17 Million USD | 39.204% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -113.562% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -363.638% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 155.394% |
| SciSparc Ltd. | -5.77 Million USD | -1070.76% |
| Vericel Corporation | -6.46 Million USD | -945.606% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -680.763% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -192.341% |
| Generation Bio Co. | -138.56 Million USD | 51.222% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 18.598% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 21.827% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 71.967% |
| Invivyd, Inc. | -207.78 Million USD | 67.472% |
| Relay Therapeutics, Inc. | -373 Million USD | 81.88% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -620.669% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 414.641% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -557.023% |
| 2seventy bio, Inc. | -216.7 Million USD | 68.811% |
| ADMA Biologics, Inc. | 21.63 Million USD | 412.445% |
| Clene Inc. | -40.54 Million USD | -66.719% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -180.706% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -23.345% |
| GeoVax Labs, Inc. | -26.74 Million USD | -152.732% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 80.692% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -84.003% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 520.402% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 34.825% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -98.777% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 60.307% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 90.123% |
| Evaxion Biotech A/S | -22.19 Million USD | -204.492% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 17.958% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 69.708% |
| Trevena, Inc. | -35.28 Million USD | -91.533% |
| Surrozen, Inc. | -45.78 Million USD | -47.637% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 15.457% |
| Cingulate Inc. | -22.75 Million USD | -196.97% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 1002.136% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -51.315% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -720.846% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 34.098% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 7.892% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -8.883% |
| Clearmind Medicine Inc. | -8.74 Million USD | -673.199% |
| Kronos Bio, Inc. | -121.83 Million USD | 44.523% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 11.297% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -2204.41% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 32.966% |
| Statera Biopharma, Inc. | -98.34 Million USD | 31.274% |
| ImmunityBio, Inc. | -362.25 Million USD | 81.342% |
| Korro Bio, Inc. | -84.53 Million USD | 20.046% |
| Kineta, Inc. | -15.72 Million USD | -329.867% |
| BioVie Inc. | -32.17 Million USD | -110.034% |
| Codexis, Inc. | -68.06 Million USD | 0.707% |
| Celularity Inc. | -192.28 Million USD | 64.85% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 69.638% |
| Celcuity Inc. | -66.23 Million USD | -2.05% |
| Virax Biolabs Group Limited | -6.49 Million USD | -940.38% |
| Cibus, Inc. | -318.88 Million USD | 78.805% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -57.181% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -99.705% |
| IN8bio, Inc. | -30.33 Million USD | -122.791% |
| Kodiak Sciences Inc. | -277.32 Million USD | 75.628% |
| Annexon, Inc. | -143.72 Million USD | 52.973% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 45.402% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -4.551% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -188.296% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 80.893% |
| Eyenovia, Inc. | -25.4 Million USD | -166.027% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 307.071% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1115.174% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 14.589% |
| Arcellx, Inc. | -89.88 Million USD | 24.802% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -48.833% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 50.74% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -117.262% |
| Moolec Science SA | -6.65 Million USD | -915.78% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -10.55% |
| Geron Corporation | -193.94 Million USD | 65.151% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -56.262% |
| Royalty Pharma plc | 1.49 Billion USD | 104.53% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 58.828% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -624.582% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -208.696% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 60.465% |
| Humacyte, Inc. | -100.04 Million USD | 32.444% |
| Structure Therapeutics Inc. | -102.77 Million USD | 34.237% |
| 89bio, Inc. | -151.2 Million USD | 55.3% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 15.654% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -364.842% |
| Genelux Corporation | -24.16 Million USD | -179.694% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -99.239% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 60.647% |
| Notable Labs, Ltd. | -14.65 Million USD | -361.131% |
| Liquidia Corporation | -73.38 Million USD | 7.898% |
| Mustang Bio, Inc. | -50.72 Million USD | -33.241% |
| Immunovant, Inc. | -282.7 Million USD | 76.093% |
| Quantum-Si incorporated | -111.17 Million USD | 39.204% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 13.463% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -217.807% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 33.745% |
| Acasti Pharma Inc. | -11.31 Million USD | -497.489% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -194.872% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -322.971% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 68.425% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -1742.101% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -325.456% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -131.807% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -63.319% |
| PepGen Inc. | -84.76 Million USD | 20.265% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -128.099% |
| United Therapeutics Corporation | 1.18 Billion USD | 105.704% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -195.183% |
| Solid Biosciences Inc. | -104.31 Million USD | 35.208% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -106.01% |
| Immuneering Corporation | -58.41 Million USD | -15.707% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -1227.797% |
| Silo Pharma, Inc. | -3.85 Million USD | -1652.986% |
| Belite Bio, Inc | -31.66 Million USD | -113.427% |
| XOMA Corporation | -41.84 Million USD | -61.508% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -0.101% |
| Bionomics Limited | -17.89 Billion USD | 99.622% |
| Apogee Therapeutics, Inc. | -93 Million USD | 27.327% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 289.428% |
| uniQure N.V. | -282.87 Million USD | 76.106% |
| Cassava Sciences, Inc. | -105.95 Million USD | 36.212% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -824.584% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 47.81% |
| Forte Biosciences, Inc. | -32.48 Million USD | -108.053% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -713.455% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -129.93% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -1115.174% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -375.637% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -660.355% |
| Altimmune, Inc. | -95.92 Million USD | 29.544% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 8.036% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 289.428% |
| Compugen Ltd. | -12.99 Million USD | -420.228% |
| Peak Bio, Inc. | -1356.23 USD | -4983420.494% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -36.255% |
| Benitec Biopharma Inc. | -22.49 Million USD | -200.525% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 72.106% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -127.217% |
| Zura Bio Limited | -62.63 Million USD | -7.903% |
| PolyPid Ltd. | -22.86 Million USD | -195.57% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -315.262% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -127.217% |
| Instil Bio, Inc. | -159.16 Million USD | 57.537% |
| argenx SE | -425.04 Million USD | 84.099% |
| Immunome, Inc. | -109.53 Million USD | 38.293% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -34.202% |
| Verona Pharma plc | -67.83 Million USD | 0.358% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -159.355% |
| Shattuck Labs, Inc. | -91.95 Million USD | 26.5% |
| CervoMed Inc. | -7.81 Million USD | -765.083% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 7.553% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -407.379% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -40.3% |
| Moolec Science SA | -6.65 Million USD | -915.78% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -310.908% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 50.019% |
| AnaptysBio, Inc. | -164.41 Million USD | 58.891% |
| Design Therapeutics, Inc. | -78.19 Million USD | 13.559% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 22.349% |
| NeurAxis, Inc. | -6.66 Million USD | -914.15% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -66.888% |
| Lumos Pharma, Inc. | -36.61 Million USD | -84.596% |
| Achilles Therapeutics plc | -75.25 Million USD | 10.188% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -159.355% |
| 180 Life Sciences Corp. | -13.47 Million USD | -401.488% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 1410.782% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -2204.41% |
| Nutriband Inc. | -4.87 Million USD | -1287.295% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 38.989% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -21.892% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -32.953% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -2.253% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -24.878% |
| Palisade Bio, Inc. | -13.07 Million USD | -417.123% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -48.843% |
| Beam Therapeutics Inc. | -176.48 Million USD | 61.703% |
| Neurogene Inc. | -55.58 Million USD | -21.598% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 38.08% |
| AEON Biopharma, Inc. | -48.42 Million USD | -39.561% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 30.113% |
| Sesen Bio, Inc. | -25.9 Million USD | -160.867% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 19.084% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -436.971% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 85.325% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 6.697% |
| Athira Pharma, Inc. | -125.46 Million USD | 46.13% |
| Vaccinex, Inc. | -22.88 Million USD | -195.338% |
| HCW Biologics Inc. | -25.71 Million USD | -162.813% |
| XOMA Corporation | -41.84 Million USD | -61.508% |
| Nektar Therapeutics | -137.42 Million USD | 50.818% |
| Arvinas, Inc. | -401.5 Million USD | 83.166% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -764208.161% |
| Merus N.V. | -156.54 Million USD | 56.826% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 32.588% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -95.228% |
| Rezolute, Inc. | -70.42 Million USD | 4.026% |
| Clene Inc. | -40.54 Million USD | -66.719% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -312.664% |
| BeyondSpring Inc. | -23.11 Million USD | -192.412% |
| Synlogic, Inc. | -55.16 Million USD | -22.529% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -276.976% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -524.427% |
| Peak Bio, Inc. | -1356.23 USD | -4983420.494% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -66.872% |
| Krystal Biotech, Inc. | -109.72 Million USD | 38.403% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 47.825% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 80.296% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -1324.119% |
| MannKind Corporation | 8.67 Million USD | 878.843% |
| Ikena Oncology, Inc. | -75.41 Million USD | 10.381% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -600.612% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -0.533% |
| Gossamer Bio, Inc. | -183.75 Million USD | 63.219% |
| CohBar, Inc. | -12.38 Million USD | -445.579% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -33.247% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -144.999% |
| Legend Biotech Corporation | -439.48 Million USD | 84.621% |
| Mural Oncology plc | -194.63 Million USD | 65.275% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -0.663% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -318.624% |
| Disc Medicine, Inc. | -91.12 Million USD | 25.829% |
| Champions Oncology, Inc. | -7.35 Million USD | -818.815% |
| REGENXBIO Inc. | -268.12 Million USD | 74.793% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -530.592% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -21.221% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -73.478% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 40.897% |
| Vaxart, Inc. | -83.34 Million USD | 18.908% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -693.286% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -57.938% |
| Cellectis S.A. | -106.62 Million USD | 36.612% |
| Longeveron Inc. | -21.02 Million USD | -221.404% |
| Repare Therapeutics Inc. | -116.22 Million USD | 41.847% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 74.764% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 10.651% |
| Revolution Medicines, Inc. | -487.18 Million USD | 86.127% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -916.055% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -53.77% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 9.387% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 2.94% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -513.823% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.569% |
| Denali Therapeutics Inc. | -196.69 Million USD | 65.639% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -680.763% |
| Veru Inc. | -93.78 Million USD | 27.931% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -189.717% |
| Cingulate Inc. | -22.75 Million USD | -196.97% |
| Passage Bio, Inc. | -108.38 Million USD | 37.643% |
| Context Therapeutics Inc. | -25.07 Million USD | -169.569% |
| Exicure, Inc. | -14.99 Million USD | -350.707% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 67.2% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -66.481% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -595.569% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 63.339% |
| Nuvalent, Inc. | -149.49 Million USD | 54.788% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -722.588% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 23.828% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -225.349% |
| OmniAb, Inc. | -69.41 Million USD | 2.638% |
| Anew Medical, Inc. | -1.3 Million USD | -5095.72% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -429.23% |
| Lipocine Inc. | -17.93 Million USD | -276.935% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 1.35% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 11.246% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -77.511% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -70.992% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -201.948% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 88.344% |
| Ocugen, Inc. | -65.53 Million USD | -3.139% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 27.995% |
| Q32 Bio Inc. | -92.1 Million USD | 26.616% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -215.257% |
| Alumis Inc. Common Stock | -158.17 Million USD | 57.27% |
| Equillium, Inc. | -14.52 Million USD | -365.418% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -8.304% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -755.182% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -258.27% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -43.954% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 37.687% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -464.644% |
| Dominari Holdings Inc. | -21.79 Million USD | -210.094% |
| Edesa Biotech, Inc. | -9.22 Million USD | -632.839% |
| vTv Therapeutics Inc. | -25.5 Million USD | -165.03% |
| Bio-Techne Corporation | 206.68 Million USD | 132.701% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 82.736% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 135.197% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 48.904% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -76.052% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 55.27% |
| Nkarta, Inc. | -131.65 Million USD | 48.661% |
| BioCardia, Inc. | -11.64 Million USD | -480.453% |
| Iterum Therapeutics plc | -47.46 Million USD | -42.386% |